Abstract:Objective: The aim of this study was to evaluate the efficacy of a new ultrasound contrast agent, SonoVue, in diagnosis and differential diagnosis of liver lesions.Methods: Thirty-one patients with difficult differential diagnosis or highly suspected for liver lesions on CT, MRI, or conventional US were studied. A dose of 2.4 ml of SonoVue (Bracco, Italy) was infused intravenously within 30 sec. The enhancement level was monitored with a nonlinear scanning mode using an Acuson Sequoia-512 scanner with 6C-2, 4C-1 probes. The comparison examinations were performed with physical examination in all cases and with library examination in 16 patients before and after SonoVue injection. The histopathalogical diagnoses were obtained in 20 patients after SonoVue enhanced US examination. The other diagnoses were confirmed on CT, MRI, and DSA. Twenty patients had malignant liver lesions (16 hepatocellular carcinomas, 4 metastases), while 11 had benign lesions (4 hemangiomas, 2 focal nodular hyperplasias, 5 others).Results: 1) After SonoVue injection, the number of lesions without flow signal intralesions dropped from 15 to 2 with nonlinear scanning modes. 2) The positive diagnoses compared to the histopathalogical diagnoses increased after SonoVue in nonlinear scanning modes (p<0.05). 3) There was no difference in physical examination and library examinations before and after SonoVue injection.Conclusions: SonoVue is useful in visualizing tumor vessel and characterizing liver tumors. It is a safe, efficient ultrasound contrast agent and convenient for use. Objective: The aim of this study was to evaluate the efficacy of a new ultrasound contrast agent, SonoVue, in diagnosis and differential diagnosis of liver lesions. Methods: Thirty-one patients with difficult differential diagnosis or highly suspected for liver lesions on CT, MRI, or conventional US were studied. A dose of 2.4 ml of SonoVue (Bracco, Italy) was infused intravenously within 30 sec. The enhancement level was monitored with a nonlinear scanning mode using an Acuson Sequoia-512 scanner with 6C-2, 4C-1 probes. The comparison examinations were performed with physical examination in all cases and with library examination in 16 patients before and after SonoVue injection. The histopathalogical diagnoses were obtained in 20 patients after SonoVue enhanced US examination. The other diagnoses were confirmed on CT, MRI, and DSA. Twenty patients had malignant liver lesions (16 hepatocellular carcinomas, 4 metastases), while 11 had benign lesions (4 hemangiomas, 2 focal nodular hyperplasias, 5 others). Results: 1) After SonoVue injection, the number of lesions without flow signal intralesions dropped from 15 to 2 with nonlinear scanning modes. 2) The positive diagnoses compared to the histopathalogical diagnoses increased after SonoVue in nonlinear scanning modes (p<0.05). 3) There was no difference in physical examination and library examinations before and after SonoVue injection. Conclusions: SonoVue is useful in visualizing tumor vessel and characterizing liver tumors. It is a safe, efficient ultrasound contrast agent and convenient for use.

Anaphylaxis after SonoVue: A Case Report and a Literature Review

Adverse Reactions after the Use of SonoVue Contrast Agent

Adverse reactions analysis and safety management associated with SonoVue

Safety of Sulfur Hexafluoride Microbubbles in Sonography of Abdominal and Superficial Organs: Retrospective Analysis of 30,222 Cases

Contrast-enhanced ultrasound imaging of the liver: a review of the clinical evidence for SonoVue and Sonazoid

A Phase 3 Multicentre, Randomised, Comparative Study of the Efficacy and Safety of Sonazoid and SonoVue in Subjects with Focal Liver Lesions Undergoing Pre- and Post-Contrast Ultrasound Imaging

Safety Analysis of Adverse Events of Ultrasound Contrast Agent Lumason/SonoVue in 49,100 Patients

Safety of Lumason® (SonoVue®) in special populations and critically ill patients

Management of acute coronary syndromes requiring coronary angiography in patients with drug reaction with eosinophilia and systemic symptoms syndrome induced by iodinated contrast media: two case reports and narrative review

Laryngeal edema following remimazolam-induced anaphylaxis: a rare clinical manifestation

The Incidence, Classification, and Management of Acute Adverse Reactions to the Low-Osmolar Iodinated Contrast Media Isovue and Ultravist in Contrast-Enhanced Computed Tomography Scanning.

Anaphylaxis following a transvaginal ultrasound

Airway collapse as the predominant clinical feature following remimazolam-induced anaphylaxis: a case report

Anaphylactic risk associated with iodinated and gadolinium-based contrast media

Improved differential diagnosis of focal liver disease using SonoVue with nonlinear scanning mode

A Case of Severe Lethal Allergic Reaction Caused by Iodixanol After Digital Subtraction Angiography

Amiodarone-Induced Anaphylaxis

A Review of Contrast-enhanced Ultrasound using SonoVue® and Sonazoid TM in Non-hepatic Organs

Stroke in a patient of anaphylaxis-a case report and brief review

Adverse reactions to intravenous iodinated contrast media: an update

Anaphylactic Shock as a Rare Side Effect of Intravenous Amiodarone